DYCKMAN, Alaric J.,DODD, Dharmpal S.,HAQUE, Tasir Shamsul,LOMBARDO, Louis J.,MACOR, John E.,MUSSARI, Christopher P.,PASUNOORI, Laxman,RATNA KUMAR, Sreekantha,SHERWOOD, Trevor C.,POSY, Shoshana L.,SIST
申请号：
PE2018003329
公开号：
PE20190324A1
申请日:
2017.06.28
申请国别(地区):
PE
年份:
2019
代理人:
摘要：
It refers to a formula compound (I) or a salt, whose characteristic is that R1 is h, Cl and CN, and each R2 is independent of halogen, CN and oh. -2+,Among other things, R3 is (a) - l1-a； or (b) h, C1-6 hydrocarbon, c1-3 fluoropropyl compound, etc.； L1 is a link, - (crxrx) 1-2 -.-（Crxrx）1-2Among other things, a is 2-oxa-6-azazario [3.3] heptanilo, 4-oxapiro [2.5] octanium； each R4 is an independent f-oh C1-2 asphalt, etc.； each R5 is an independent F, cl-cn, etc.； m is 0, 1, 2, 3 or 4； n is 0, 1 or 2； P is 0, 2, 3 or 4. These compounds are indole compounds substituted by [1.2.4] triazole [1.5-A] pyridine, which inhibit the unsterilized by toll 7, 8 or 9 type receivers (tl7, tl8, tl9). It also refers to the composer of pharmacology who contains the compound. These compounds can be used to treat chronic and autoimmune inflammation.Referido a un compuesto de formula (I) o una sal del mismo, caracterizado porque R1 es H, Cl, -CN, entre otros； cada R2 es, independientemente halo, -CN, -OH. -NO2+, entre otros； R3 es (a) -L1-A； o (b) H, alquilo C1-6, fluoroalquilo C1-3, entre otros； L1 es un enlace, -(CRxRx)1-2-, -(CRxRx)1-2O-, entre otros； A es 2-oxa-6-azaespiro[3.3]heptanilo, 4-oxaspiro[2.5]octanilo, entre otros； cada R4 es independientemente F, -OH, alquilo C1-2, entre otros； cada R5 es independientemente F, Cl, -CN, entre otros； m es 0, 1, 2, 3 o 4； n es 0, 1 o 2； y p es 0, 1, 2, 3, o 4. Estos, son compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo, siendo inhibidores de la senalizacion a traves del receptor tipo Toll 7, 8 o 9 (TLR7, TLR8, TLR9). Tambien se refiere a composiciones farmaceuticas que comprenden tales compuestos. Estos compuestos son utiles para tratar enfermedades inflamatorias cronicas y autoinmunitarias.
